Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBVX.L Regulatory News (BVX)

  • There is currently no data for BVX

Holding(s) in Company

19 Jan 2023 07:00

RNS Number : 1958N
BiVictriX Therapeutics PLC
19 January 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

gb00bnxh3k91

Issuer Name

BIVICTRIX PLC

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Robert Napier Keith

City of registered office (if applicable)

London

Country of registered office (if applicable)

UK

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

18-Jan-2023

6. Date on which Issuer notified

18-Jan-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

10.410000

7.780000

18.190000

12027760

Position of previous notification (if applicable)

9.970000

7.070000

17.040000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BNXH3K91

6883434

10.410000

Sub Total 8.A

6883434

10.410000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

SPREADBET

5144326

7.780000

Sub Total 8.B1

5144326

7.780000%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUWOURORUAAUR
12
Date   Source Headline
11th Sep 20247:00 amRNSCancellation - BiVictriX Therapeutics plc
10th Sep 202411:04 amRNSHolding(s) in Company
10th Sep 20247:00 amRNSLast Day of Dealings
9th Sep 20247:00 amRNSPositive In Vivo Data from BVX002 Programme
2nd Sep 20245:04 pmRNSHolding(s) in Company
2nd Sep 20248:50 amRNSDirector Dealing
29th Aug 20245:05 pmRNSResult of General Meeting
28th Aug 202410:14 amRNSHolding(s) in Company
28th Aug 202410:12 amRNSHolding(s) in Company
19th Aug 20247:00 amRNSTR-1: Notification of major holdings
13th Aug 20247:00 amRNSGrant of Options
12th Aug 20247:00 amRNSProposed Voluntary Delisting
1st Aug 20247:00 amRNSInterim Results
24th Jul 20245:00 pmRNSResult of Annual General Meeting
26th Jun 20247:00 amRNSPublication of 2023 Annual Report & Notice of AGM
13th Jun 20247:00 amRNSCompelling Safety Profile of BVX001
6th Jun 20247:00 amRNSInnovate UK Grant Award to Accelerate ADC Pipeline
31st May 20248:44 amRNSBiVictriX – Full Year Results 2023
17th Apr 20247:00 amRNSOrphan Drug Designation & FDA INTERACT Meeting
28th Mar 20247:00 amRNSGrant of Options – PDMR/Director Dealings
4th Jan 202412:30 pmRNSHolding(s) in Company
4th Jan 202412:30 pmRNSHolding(s) in Company
4th Jan 20247:00 amRNSBiVictriX Hosts Inaugural Roundtable Discussion
5th Dec 202311:08 amRNSBoard Change
30th Nov 20237:00 amRNSPipeline update on BVX002
22nd Nov 20235:14 pmRNSHolding(s) in Company
15th Nov 20237:00 amRNSPatent Granted in Japan
12th Oct 20237:00 amRNSExtended Survival Rates Reported with BVX001
3rd Oct 20237:00 amRNSAppointment of Adrian Howd as CFO and CBO
19th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSTotal Voting Rights
23rd Aug 20237:00 amRNSUS Patent Granted
17th Aug 20237:00 amRNSHolding(s) in Company
16th Aug 20236:00 pmRNSHolding(s) in Company
11th Aug 20234:17 pmRNSHolding(s) in Company
8th Aug 20235:18 pmRNSResult of General Meeting
19th Jul 20236:16 pmRNSResult of Conditional Fundraise
19th Jul 202312:31 pmRNSProposed Fundraise in excess of £2 million
17th Jul 20237:00 amRNSPositive final data in preclinical efficacy study
19th Jun 20237:00 amRNSPositive interim data
6th Jun 20237:00 amRNSBiVictriX nominates clinical candidate for BVX001
4th May 20234:36 pmRNSResult of Annual General Meeting
31st Mar 20237:00 amRNSPublication of Annual Report and Notice of AGM
30th Mar 20237:00 amRNSBiVictriX Full Year Results
1st Mar 20237:01 amRNSAppointment of Alex Hughes as CFO
31st Jan 20237:08 amRNSBiVictriX reports positive BVX001 preclinical data
24th Jan 20234:21 pmRNSHolding(s) in Company
19th Jan 202311:00 amRNSHolding(s) in Company
19th Jan 20237:00 amRNSHolding(s) in Company
16th Jan 20234:32 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.